NCT06303414 Revascularization for Symptomatic Non-acute Carotid Artery Occlusion
| NCT ID | NCT06303414 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xuanwu Hospital, Beijing |
| Condition | Non-acute Carotid Artery Occlusion |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2016-06-17 |
| Primary Completion | 2028-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2016-06-17 with a primary completion date of 2028-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The short-term and long-term efficacy of recanalization therapy needs to be further confirmed by large-sample prospective studies. The comparison of success rate, complication rate and efficacy among the three recanalization modalities also needs to be further explored. The purpose of this cohort study is to observe the success rate, efficacy and safety of recanalization treatment for non-acute occlusion, and to further compare the advantages and disadvantages of CEA, endovascular intervention and hybrid surgery.
Eligibility Criteria
Inclusion Criteria: 1. Older than 18 years old; 2. Sign the informed consent form; 3. Carotid occlusion at least 24h; 4. Patients with clinical localization symptoms: ipsilateral hemisphere ischemia symptoms or ipsilateral eye ischemia symptoms or cognition impairment, with or without anterior circulation blood supply area infarction; 5. DSA confirmed common carotid artery or internal carotid artery (mTICI=0) occlusion; 6. Perfusion imaging confirms the presence of hypoperfusion in the corresponding area(CBF decrease); 7. The optimal medical treatment for patients who still have ischemic symptoms; 8. Routine DWI and ADC sequence examinations are performed before surgery no new infarction; Exclusion Criteria: 1. Intracranial arteriovenous malformation or aneurysm; 2. Unstable angina, myocardial infarction (MI), or congestive heart failure in the last 6 months; 3. Uncontrolled diabetes mellitus defined as glucose \> 300 mg/dL (16.67 mmol/L); 4. Patient is expected to have the ADP antagonist therapy interruption within 3 months after the procedure; 5. Pregnant or in the perinatal period; 6. Severe concomitant disease with poor prognosis (life expectancy \< 3 years); 7. Intolerance or allergies to any of the study medications, such as aspirin or clopidogrel; 8. Allergy to iodine or radiographic contrast media; 9. Concomitant vascular conditions precluding endovascular; 10. Patients with large cerebral infarction within 2 weeks; 11. History of ipsilateral vocal cord paralysis; 12. Those with severe skin diseases who are expected to have difficulty healing the incision; 13. Poor functional status before onset (mRS score 4-5 points). 14. The area of infarction in the occluded vascular area exceeds half of the vascular supply area; 15. Already have dementia or psychiatric illness and are unable to complete neurological and cognitive assessments. 16. Any condition that in the surgeon's judgment suggests the patient an unsuitable surgical candidate.
Frequently Asked Questions
Who can join the NCT06303414 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Non-acute Carotid Artery Occlusion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06303414 currently recruiting?
Yes, NCT06303414 is actively recruiting participants. Visit ClinicalTrials.gov or contact Xuanwu Hospital, Beijing to inquire about joining.
Where is the NCT06303414 trial being conducted?
This trial is being conducted at Beijing, China, Beijing, China.
Who is sponsoring the NCT06303414 clinical trial?
NCT06303414 is sponsored by Xuanwu Hospital, Beijing. The trial plans to enroll 1,000 participants.